SOLICITATION NOTICE
B -- DNA Samples for Library Construction
- Notice Date
- 8/25/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-(HG)-2014-239-DLM
- Archive Date
- 9/19/2014
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Heart, Lung, and Blood Institute (NHLBI) and the National Human Genome Research Institute (NHGRI), intends to negotiate and award a purchase order on a non-competitive sole source basis to Cofactor Genomics, 4044 Clayton Avenue, St. Louis, MO 63110 to procure the following: Procurement: 1. Genomic DNA samples from 57 human subjects (Minimum 6 ug high-quality gDNA per subject); 114 total samples for library preparation (2 per subject - bisulfite treated and untreated samples); Agilent SureSelectXT Human MethylSeq capture and Illumina barcoded library generation; and 114 total libraries (57 bisulfite-treated, 57 non-treated); 2. Genomic DNA samples from 49 human subjects (Minimum 6 ug high-quality gDNA per subject); 98 total samples for library preparation (2 per subject - bisulfite treated and untreated samples); Agilent SureSelectXT Human MethylSeq capture and Illumina barcoded library generation; and 98 total libraries (49 bisulfite-treated, 49 non-treated). ANTICIPATED PERIOD OF PERFORMANCE: Upon Award 10-12 Weeks BACKGROUND: The National Institutes of Health (NIH) mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NHGRI/DIR Cardiovascular Disease Section (CDS) and the NHGRI/DIR Social Epidemiology Research Unit conducts a broad program of clinical and translational research seeking a greater understanding of the genomic basis of human cardiovascular disease. A major component of the research centers is understanding epigenetic modifications contributing to cardiovascular disease phenotypes such as resistant hypertension and coronary calcification. DNA methylation (a biochemical process where a methyl group is added to the cytosine or adenine DNA nucleotides) is a primary mechanism of epigenetic modification. Currently, bisulfite treatment of methylated DNA followed by next-generation sequencing (Methyl-Seq) is the gold standard experimental technique for analysis of DNA methylation. Methyl-Seq experiments can focus either on the whole genome or on specific regions of the genome known to be affected by DNA methylation (the methylome). JUSTIFICATION: The goals of the NHGRI/DIR Cardiovascular Disease Section (CDS) and NHGRI/DIR Social Epidemiology Research Unit (SERU) include identifying sites of epigenetic modifications contributing to cardiovascular disease endpoints such as resistant hypertension and coronary calcification. Cofactor Genomics, Inc. supports the goals of the CDS and SERU. Epigenetic modifications such as DNA methylation have been implicated in cardiovascular disease, including atherosclerosis. DNA methylation polymorphisms may be used as an early biomarker of atherosclerosis since they are present before lesions are observed, which may provide an early tool for detection and risk prevention Therefore, it is an essential component of the GENE-FORECASTSM study's in-depth cardiovascular phenotyping. REGULATORY AUTHORITY: This acquisition is conducted under the authority of 41 U.S.C. 253(c) as set forth in FAR Part 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements. ADDITIONAL INFORMATION: Industry Classification (NAICS) Code is 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) and the Small Business Size Standard is 500 Employees. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001). The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-76 (August 25, 2014). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by September 4, 2014 and must reference synopsis number HHS-NIH-NHLBI-CSB-(HG)-2014-239-DLM, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-(HG)-2014-239-DLM/listing.html)
- Record
- SN03479040-W 20140827/140826000007-af5a6dcd32e5e1d09b536af6a1c1dcf3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |